NCT07666113 · RECRUITING
Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.
This study looks at a blood test for p-tau217, a protein linked to Alzheimer's changes in the brain, used in a regular primary care office. Researchers want to see how the results change what happens next for people worried about their memory or thinking. Phase is not applicable because it tests a diagnostic tool, not a drug.
You may qualify if
- Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.
You're excluded if
- Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).
- Concomitant medications that would interfere with cognitive assessments.
- A prior diagnosis of AD and related disorders or other neurodegenerative disease.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-06-24